These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 2172594

  • 1. [Comparative study of low molecular weight heparin and unfractionated heparin in patients on maintenance hemodialysis].
    Noguchi M, Izumi K, Deguchi K, Endoh T, Tsuda M, Shirakawa S.
    Rinsho Byori; 1990 Jul; Suppl 86():177-83. PubMed ID: 2172594
    [No Abstract] [Full Text] [Related]

  • 2. Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure.
    Lane DA, Ireland H, Tew CJ, Flynn A, Curtis JR.
    Acta Chir Scand Suppl; 1988 Jul; 543():101-4. PubMed ID: 2847457
    [Abstract] [Full Text] [Related]

  • 3. Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients.
    Poyrazoglu OK, Dogukan A, Yalniz M, Seckin D, Gunal AL.
    Ren Fail; 2006 Jul; 28(8):723-7. PubMed ID: 17162433
    [Abstract] [Full Text] [Related]

  • 4. [Effects of low molecular weight heparin as an anti-coagulant for hemodialysis].
    Akizawa T, Kanamori N, Koshikawa S.
    Rinsho Byori; 1990 Jul; Suppl 86():171-6. PubMed ID: 2172593
    [No Abstract] [Full Text] [Related]

  • 5. [Use of low-molecular weight heparin during hemodialysis].
    Kalinowski M, Pawlak K, Myśliwiec M, Popławski A.
    Pol Merkur Lekarski; 1997 Jan; 2(9):208-10. PubMed ID: 10907031
    [Abstract] [Full Text] [Related]

  • 6. Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis.
    Liu ZQ, Wang L.
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Oct; 22(10):942-3. PubMed ID: 12377628
    [Abstract] [Full Text] [Related]

  • 7. Anti-factor Xa determination in blood: a new method for controlling heparin therapy.
    Harenberg J, Haaf B, Schäfer M, Dempfle CE, Stehle G, Heene DL.
    Semin Thromb Hemost; 1993 Oct; 19 Suppl 1():79-85. PubMed ID: 8395736
    [No Abstract] [Full Text] [Related]

  • 8. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J, Haaf B, Dempfle CE, Stehle G, Heene DL.
    Nephrol Dial Transplant; 1995 Oct; 10(2):217-22. PubMed ID: 7753456
    [Abstract] [Full Text] [Related]

  • 9. Coagulation and fibrinolysis in patients with chronic renal failure on maintenance hemodialysis.
    Deguchi K, Izumi K, Noguchi M, Yuwasaki E, Suzuki H, Mori Y, Deguchi A, Ohkubo I, Tsuda M, Wada H.
    Nihon Ketsueki Gakkai Zasshi; 1989 Feb; 52(1):140-6. PubMed ID: 2741646
    [Abstract] [Full Text] [Related]

  • 10. [Changes in platelets, coagulation and fibrinolysis in patients with chronic kidney diseases and hemodialysis].
    Terada H.
    Nihon Rinsho; 1992 Jan; 50 Suppl():565-72. PubMed ID: 1578739
    [No Abstract] [Full Text] [Related]

  • 11. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.
    Moia M, Graziani G, Tenconi PM, Martinelli I, Ponticelli C.
    Ann Ital Med Int; 1997 Jan; 12(2):67-71. PubMed ID: 9284597
    [Abstract] [Full Text] [Related]

  • 12. Low-molecular-weight heparin for routine hemodialysis.
    Davenport A.
    Hemodial Int; 2008 Oct; 12 Suppl 2():S34-7. PubMed ID: 18837768
    [Abstract] [Full Text] [Related]

  • 13. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis.
    Ljungberg B, Blombäck M, Johnsson H, Lins LE.
    Clin Nephrol; 1987 Jan; 27(1):31-5. PubMed ID: 3815906
    [Abstract] [Full Text] [Related]

  • 14. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
    Frank RD, Müller U, Lanzmich R, Groeger C, Floege J.
    Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
    [Abstract] [Full Text] [Related]

  • 15. [Use in hemodialysis and hemofiltration of CY 216 (Fraxiparine) administered via intravenous bolus in patients with acute and chronic renal insufficiency with and without hemorrhagic risk].
    Steinbach G, Bosc C, Caraman PL, Azoulay E, Olry L, D'Azemar P, Chopin J.
    Nephrologie; 1990 Apr; 11(1):17-21. PubMed ID: 2165223
    [Abstract] [Full Text] [Related]

  • 16. Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients.
    Kronenberg F, König P, Lhotta K, Steinmetz A, Dieplinger H.
    Clin Nephrol; 1995 Jun; 43(6):399-404. PubMed ID: 7554525
    [Abstract] [Full Text] [Related]

  • 17. Effects of low molecular weight heparin on the frequencies of intradialytic arrhythmias in hemodialysis patients.
    Miyauchi H, Matsumoto Y, Futenma A, Amano I, Miyauchi J, Matsuo S.
    Ren Fail; 2006 Jun; 28(6):469-74. PubMed ID: 16928615
    [Abstract] [Full Text] [Related]

  • 18. [Disorders of blood coagulation and fibrinolysis in patients with chronic renal failure during treatment with hemodialysis, and methods of correction].
    Neĭmark MI.
    Ter Arkh; 1984 Jun; 56(7):48-53. PubMed ID: 6484834
    [No Abstract] [Full Text] [Related]

  • 19. [Present opinions concerning the administration of low molecular weight heparins in hemodialysis patients].
    Drozdz M, Kowalczyk-Michałek M, Kraśniak A, Sułowicz W.
    Przegl Lek; 2005 Jun; 62(4):257-9. PubMed ID: 16229247
    [Abstract] [Full Text] [Related]

  • 20. Comparison of low molecular weight heparin and standard heparin in hemodialysis.
    Bambauer R, Rücker S, Weber U, Köhler M.
    ASAIO Trans; 1990 Jun; 36(3):M646-9. PubMed ID: 2174689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.